Catalysts for $ABBV

AbbVie Inc. earnings

AbbVie Inc. earnings

AbbVie Inc. earnings

AbbVie Inc — venetoclax (Phase I/II Trial Completion)

AbbVie Inc — blinatumomab (Phase I/II Trial Completion)

AbbVie Inc. earnings

UNIV OF NORTH CAROLINA CHAPEL HILL — A Trial of Upadacitinib for Non-responsive Eosinophilic esophagitis (ATUNE)

DEPAKOTE (DIVALPROEX SODIUM) — FDA approval

DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approval

DEPAKOTE (DIVALPROEX SODIUM) — FDA approval

ESCITALOPRAM OXALATE — FDA approval

ESCITALOPRAM OXALATE — FDA approval

ESCITALOPRAM OXALATE — FDA approval

ESCITALOPRAM OXALATE — FDA approval

ESCITALOPRAM OXALATE — FDA approval

ESCITALOPRAM OXALATE — FDA approval

ESCITALOPRAM OXALATE — FDA approval

ESCITALOPRAM OXALATE — FDA approval

ESCITALOPRAM OXALATE — FDA approval

VYALEV (FOSCARBIDOPA) — FDA approval

DUOPA (CARBIDOPA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

COMBIGAN (BRIMONIDINE TARTRATE) — FDA approval

OZURDEX (DEXAMETHASONE) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

VENCLEXTA (VENETOCLAX) — FDA approval

AbbVie — Natrelle 133S Tissue Expanders (510k cleared)

HUMIRA (ADALIMUMAB) — FDA approval